CD22 Antibodies

CD22 Antibodies

Gene Name: CD22 (Cluster of Differentiation 22)

Function: CD22 is a cell surface protein belonging to the immunoglobulin superfamily. It is primarily expressed on B cells and plays a role in regulating B cell activation and signaling. CD22 acts as an inhibitory receptor that modulates B cell receptor (BCR) signaling and helps to prevent excessive activation of B cells.

Immune Regulation: CD22 is involved in regulating B cell responses to antigens and maintaining immune tolerance. By dampening BCR signaling, CD22 helps to prevent the activation of autoreactive B cells and the production of autoantibodies, thereby contributing to immune homeostasis and preventing autoimmune diseases.

Apoptosis: While CD22 itself does not directly induce apoptosis, dysregulation of CD22 signaling can affect B cell survival and contribute to the pathogenesis of certain B cell malignancies. Aberrant CD22 expression or function has been observed in B cell lymphomas and leukemias, highlighting its potential role in apoptosis regulation in these diseases.

Research Implications: Understanding the functions of CD22 is important for elucidating the mechanisms underlying B cell regulation and immune tolerance. Research on CD22 may have implications for the development of therapies targeting B cell-related diseases, including autoimmune disorders and B cell malignancies.

Clinical Relevance: CD22 has emerged as a therapeutic target for immunotherapy in B cell malignancies. Monoclonal antibodies targeting CD22, such as inotuzumab ozogamicin, have been developed for the treatment of B cell acute lymphoblastic leukemia (B-ALL) and other CD22-positive malignancies. Additionally, CD22-directed CAR-T cell therapies are being investigated as a promising approach for treating B-ALL and other CD22-positive hematological malignancies.